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Abstract Myasthenia gravis (MG) can be difficult to treat
despite an available therapeutic armamentarium. Our aim
was to analyze the factors leading to unsatisfactory out-
come (UO). To this end we used the Myasthenia Gravis
Foundation of America classification system. Forty one
patients with autoimmune MG were followed prospectively
from January 2003 to December 2007. Outcomes were
assessed throughout follow-up and at a final visit.
‘Unchanged’, ‘worse’, ‘exacerbation’ and ‘died of MG’
post-intervention status were considered UOs. During
follow-up, UO rates reached 54% and were related to
undertreatment (41%), poor treatment compliance (23%),
infections (23%), and adverse drug effects (13%). The UO
rate at final study assessment was 20%. UO during follow-
up was significantly (P = 0.004) predictive of UOs at final
assessment. When care was provided by neuromuscular
(NM) specialists, patients had significantly better follow-up
scores (P = 0.01). At final assessment UO rates were 7%
and significantly better in patients treated by NM special-
ists, compared to other physicians where UO rates reached
27%. UO was a frequent finding occurring in more than
half our patients during follow-up. Nearly two-thirds of the
UOs could have been prevented by appropriate therapeutic
adjustments and improved compliance. The differential UO
rates at follow-up, their dependency on the degree to which
the management was specialized and their correlation with
final outcomes suggest that specialized MG care improves
outcomes.
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Introduction
Fluctuating muscle weakness, with or without remission or
exacerbation, is characteristic of myasthenia gravis (MG),
an autoimmune disease of the postsynaptic neuromuscular
(NM) junction. Disease modifying immunotherapy aims to
achieve complete, or near complete, remission within a few
months [10, 12] allowing patients to resume their daily
activities in full. This response has to be maintained and
exacerbation prevented, but in practice this can be difficult
to achieve. We report the results of a prospective study
performed to assess the rate and causes of unsatisfactory
outcomes (UOs).
Methods
We conducted a prospective non-randomised observational
study from January 2003 to December 2007. A 36 item
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database was constructed to facilitate analysis of demo-
graphic, clinical, electrophysiological, pharmacological,
immunological, surgical, histological and therapeutic data.
Patients
All patients examined at our hospital were included con-
secutively, provided they had (1) a clinical picture com-
patible with MG, and (2) at least one of the following
abnormal tests: a significant decrement in the evoked
compound motor action potentials ([10%) after repetitive
nerve stimulation (RNS) of at least two nerves, abnormal
jitter or blocking on single fiber electromyography [1];
positive anti-acetylcholine receptor (AChR) antibodies
with a titer greater than 0.5 nmol/l or anti-muscle-specific
tyrosine kinase (MuSK) antibodies at greater than
0.05 nmol/l. The same neurologist from the neuromuscular
treatment center examined all patients at diagnosis and
identified patients for inclusion in the study. Follow-up
examinations were then performed by either neurologists
with NM subspecialty training (NM neurologists), or by
other hospital or primary care neurologists. NM neurolo-
gists had the Swiss board certification in neurology and in
neurophysiology and had a special training at the Institute
of Myology in Paris. The follow-up mode was determined
by patient choice (as allowed by the Swiss insurance sys-
tem) or referral mode (hospitalized patients in different
units versus those attending outpatient clinics); subse-
quently, the patients were divided in two groups, one in
which patients were under the care of NM neurologists, and
a second in which the patients received treatment from
other neurologists (Fig. 1).
Clinical evaluation and outcome measures
Patients were scored according to the Myasthenia Gravis
Foundation of America (MGFA) classification system [6].
Assessments were performed at least three times by the
NM neurologist: at the ‘diagnostic visit’, ‘during follow-
up’ (which included every assessment between the first and
final visit) and at the ‘final visit’. Pre-treatment disease
severity was determined by clinical score on the MGFA
Classification [6]. Follow-up assessments were scored
using the companion MGFA post-intervention status.
These scores were used to assess response to therapy.
‘Unchanged’, ‘worse’, ‘exacerbation’ and ‘died of MG’
were considered UOs. Among these, ‘unchanged’ was
considered the least severe, and ‘died of MG’ the worst
outcome. If a patient was found to have more than one UO
during follow-up, only the worst score was considered and
associated precipitating factors were statistically analyzed
during that time. ‘Complete, stable remission’, ‘pharma-
cologic remission’, ‘minimal manifestations’, and
‘improved’ post-intervention status were all considered
satisfactory outcomes.
Treatment
Patient treatment regimes were stratified and recorded with
the MGFA Therapy Status classification. Therapeutic
Type of follow-up, n
Mestinon & prednisone, n (%)
Unsatisfactory outcome, follow-up**, n (%)
Unsatisfactory outcome, last visit, n (%)
Mestinon & prednisone & immunosuppressant, n (%)
Neuromuscular
neurologists, 15
Other 
neurologists, 26
0
14 (93)
1 (4)
15 (58)
18 (69)
1 (7)
4 (27)
7 (27)
MG patients
n = 41
Mestinon as single therapy, n (%)  0 8 (31) 
Intravenous immunoglobulins, n (%) 3 (20)
 
9 (35)
Plasma exchange, n (%) 0 4 (15)
Mestinon & immunosuppressant, n (%) 1(7) 2 (8)
Mean delay to prednisone start
Mean delay to immunosupressant start
10 days
21 days
300 days
540 days
Fig. 1 Treatment regimen and
rate of unsatisfactory outcome
correlated with care provider
group. ** Statistical
significance (P = 0.01) of the
difference between
unsatisfactory outcome rates in
the two patient groups during
follow-up. Immunosuppressant
refers to treatment with
azathioprine, mycophenolate
mofetil or cyclosporine
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complications were defined as those directly related to any
form of specific therapy, such as drug use, operations or
radiotherapy. These were reported as adverse effects (AEs).
The MGFA morbidity and mortality classification consid-
ers infections separately, even if triggered by therapeutic
agents. Drug complications were considered related to
treatment if they developed during the treatment period,
resolved after drug discontinuation or dosage adjustment,
and had no other explanation.
Statistical analysis
Data were analyzed for the study end point and for causes
of UOs. We specified interactions a priori, assuming they
could influence UOs during follow-up or at the final
assessment. The main variables studied were: age at onset,
clinical severity at onset (MGFA Clinical Classification),
associated co-morbidities, presence and type of antibodies
(against AChR or MuSK), electromyographic results,
presence of thymoma, delay between first symptoms and
beginning of treatment, every independent or associated
treatment and the level of training of care providers. The
influence of UOs during follow-up on UOs at the last
assessment was also analyzed. Data were analyzed with the
Fisher’s exact test. Significance was set at P \ 0.05.
Descriptive statistics with presentation of percentages were
used according to the type of variable measured, in
particular when subgroups were small or unbalanced.
Analyses were conducted using STATA 10.1 software
(StataCorp LP, Texas, USA).
Results
Patient characteristics
Forty one patients were included in the study—the main
clinical features and types of follow-up are shown in
Table 1. Age at onset was distributed bimodally in females
(with modes in the second and eighth decades), and
Table 1 Characteristics of the
MG cohort
Data marked with asterisks refer
to mean ± SD (range) and other
data are expressed as number
(n) or percent (%). Single fiber
EMG was performed in
extensor digitorum communis
muscle
AChR acetylcholine receptor,
EMG electromyography, MGFA
Myasthenia Gravis Foundation
of America, MGFA CC MGFA
Clinical Classification, MuSK
muscle specific kinase, RNS
abnormal repetitive nerve
stimulation of at least two
different nerves (facial;
accessory, radial;
oromandibular complex)
All patients
(n = 41)
Patients treated by
neuromuscular
neurologists (n = 15)
Patients treated
by other neurologists
(n = 26)
Clinical
Sex (men:women) 21:20 9:6 12:14
Age at onset (year)* 54.0 ± 23.7 (6–86) 64.3 ± 18.2 (20–86) 48.1 ± 24.8 (6–85)
MGFA CC I 7 (17) 2 (13) 5 (20)
IIa 7 (17) 3 (20) 4 (15)
IIb 7 (17) 2 (13) 5 (20)
IIIa 5 (12) 1 (7) 4 (15)
IIIb 10 (25) 6 (40) 4 (15)
IVb 5 (12) 1 (7) 4 (15)
V 0 (0) 0 (0) 0 (0)
Thymoma 6 (15) 3 (20) 3 (11)
Follow-up time (months)* 67.9 ± 82.4 (6–384) 19.9 ± 17.8 (2–60) 95.5 ± 92.2 (6–384)
Electrodiagnostic data
RNS study 38 (93) 14 (93) 24 (92)
Abnormal 29 (76) 9 (64) 20 (83)
Normal 9 (24) 5 (36) 4 (17)
Single fiber EMG 29 (76) 14 (100) 15 (63)
Abnormal 20 (69) 9 (64) 11 (73)
Normal 9 (31) 5 (36) 4 (27)
Laboratory data
AChR antibodies 41 (100) 15 (100) 26 (100)
Positive 36 (88) 15 (100) 21 (81)
Negative 5 (12) 0 (0) 5 (19)
MuSK antibodies 5 (12) 0 (0) 5 (19)
Positive 2 (5) 0 (0) 2 (8)
Negative 3 (7) 0 (0) 3 (11)
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unimodally in males, peaking in the sixth decade. RNS was
performed in 38 patients (two refused and one could not be
performed for technical reasons). Single fiber EMG study
could be performed in 29 patients and was abnormal in
69% of those patients. In nine the RNS and single fiber
EMG findings were normal but these patients had positive
anti-AChR antibodies.
Therapeutic modalities
Once diagnosis was established, all patients were imme-
diately treated with pyridostigmine, with or without pred-
nisone, azathioprine or other immunosuppressants. Some
received intravenous immunoglobulins (IVIg), plasma
exchange (PEx), or underwent thymectomy and radio-
therapy. The mean delay from onset of symptoms to
treatment was 13.4 months (SD 23.5, range 0–111).
Twenty percent received pyridostigmine as monotherapy,
2% pyridostigmine and prednisone, and 7% pyridostigmine
and azathioprine. The combination of pyridostigmine with
prednisone (progressive doses up to 0.75 mg/kg per day)
and azathioprine (50 mg/day and then up to 2.5 mg/kg per
day), mycophenolate mofetil (500 mg/day and then up to
2 g/day) or cyclosporine (5 mg/kg per day and then related
to serum levels) was used, respectively, in 66, 3 and 2% of
our patients. Five PEx were given in each of four patients
with severe MGFA post-intervention status. IVIg (2 g/kg
over 5 days) was administrated to 12 patients. Seventeen
patients underwent thymectomy. Histological diagnosis in
these was thymoma (6/17 patients), hyperplasia (7/17),
involution (3/17), and normal (1/17). Two of the operated
thymoma patients had associated radiotherapy. Due to the
diversity of treatment combinations in such a small patient
cohort, statistical analysis of treatment effects was not
possible. The differences in therapeutic approaches in those
managed by NM neurologists and other neurologists are
shown in Fig. 1.
Therapeutic complications
Taken together, independent of any associated UOs,
infectious and therapy-specific complications (AEs)
occurred in 18/41 patients (44%). Drug related infections
and hepatic, hematologic, metabolic, ocular, cardiac,
osteoarticular and digestive AEs to prednisone and aza-
thioprine or to other immunosuppressants were observed in
16 patients (six had more than one); 2 patients suffered
from surgical complications, with vena cava replacement
needing life-long oral anticoagulation and phrenic nerve
injury. The proportion of patients with therapeutic com-
plications due to azathioprine, prednisone, plasma
exchange, thymectomy and radiotherapy was, respectively,
33 (10/30), 27 (8/30), 25 (1/4), 12 (2/17) and 50% (1/2);
IVIg had none (0/12). Therapeutic complications were
more frequently observed in those patients followed by NM
specialists (53% compared to 38 in the non-specialist
group).
Outcome measures
The UO rate in the whole cohort reached 54% (22/41)
during follow-up and was 20% (8/41) at the final assess-
ment varying significantly between the NM neurologists
and the other care groups (Fig. 1). No patient died of MG.
Outcome during follow-up was significantly better
(P = 0.01) when NM neurologists took care of patients.
UOs during follow-up were significantly (P = 0.004)
correlated with the UO rate at final assessment, implying
that experiencing a UO during follow-up was predictive of
a poor final outcome. It was notable that age at onset,
severity of clinical manifestations, associated co-morbid-
ity, presence of thymoma, abnormal EMG results, presence
and type of antibodies, longer elapsed time from first
symptoms to treatment ([3 months) and every independent
or associated treatment failed to show any statistically
significant correlation with UO rate during follow-up or at
final assessment.
Among all UOs during follow-up, 41% (9/22) were
associated with undertreatment, 23% (5/22) with poor
treatment compliance, another 23% with infectious com-
plications and 13% (3/22) with serious drug AEs such as
toxic hepatitis or intolerance to azathioprine. Nine patients
had UOs because of undertreatment: five, though seriously
weak, were treated with pyridostigmine alone (IIIb MGFA
Clinical Classification or worse); one showed a severely
fluctuating clinical score while treated by low dose aza-
thioprine alone; three patients treated with a combination
of pyridostigmine, prednisone, and azathioprine had doses
prematurely tapered despite ongoing muscle weakness.
Two were followed by NM neurologists and seven by other
neurologists.
Discussion
This prospective observational study of 41 treated MG
patients enabled us to identify and assess the frequency and
the causes of unsatisfactory outcomes (UOs) in treated MG
patients during follow-up. We also found that patients were
more likely to do better if under the care of an NM
neurologist.
Analysis of each UO during follow-up showed that
undertreatment, poor treatment compliance, infectious
complications and drug-induced AEs were causal factors
leading to worse outcome. Undertreatment was the prin-
cipal cause of UO, with a rate of 41%. Features included
J Neurol (2010) 257:338–343 341
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too-low dose of prednisone, no trial of IVIG or plasma
exchange and premature tapering of immunomodulation in
the presence of evident ongoing muscle weakness. The
common feature is inadequate immune modulation, what-
ever the treatment used [3]. Treatment modalities varied
between physicians: a combination of prednisone and
azathioprine or other immunosuppressant was used by NM
neurologists in 93% of their cases, versus 58% of those
patients treated by others. A significantly better outcome in
those treated by NM specialists, supports the notion that a
combined prednisone-immunosuppressant regimen is
effective in treating moderate to severe MG. Poor com-
pliance is a common medical concern [9]. The effects on
clinical outcome have been studied in many acute and
chronic disorders, but have been rarely assessed in MG.
Two studies have shown that remission from MG is related
to the confidence of patients in their physician [2, 7]. In our
study, poor compliance was responsible for 23% of all UOs
and was only encountered in patients with non-specialist
physicians. Possible explanations as to why compliance
was improved by having a NM specialist include the
increased frequency and regularity of visits and a greater
experience with treating MG patients. Similar findings
were reported from specialist Myasthenia Gravis Clinics
immediately after the discovery of anticholinesterases [8].
Infectious complications and drug-induced AEs were a
major cause of UOs, responsible for 36% of the total.
Infections and AEs in our cohort appeared to be related to
prednisone and azathioprine use. Prednisone complications
(27% in our study) were less frequent than previously
reported by others [11]. Part of this lower complication rate
may be due to the systematic use of proton pump inhibi-
tors, calcium and vitamin D3 supplements and regular
testing of fasting glucose levels to prevent corticosteroid-
induced complications. The azathioprine complication rate
we found was 33%, twice than published by some authors
[11], but similar to others [5], and probably related to the
relatively high doses of azathioprine that we used (2.5 mg/
kg per day).
Our study revealed that, independently of clinical
severity at onset, care by NM neurologists generated sig-
nificantly better outcome during follow-up (P = 0.01) than
that achieved by other physicians, and therefore that care
provision should be considered a prognostic factor in the
management of MG. To the best of our knowledge, such an
influence on the outcome of MG has not been reported thus
far. It provides empirical evidence that NM subspecialty
care plays a beneficial role in outcome which agrees with
results recently published by Hill and Ben-Shlomo [4] who
reported a crude 69% reduction in mortality risk when MG
patients were cared for by neurologists compared to other
hospital physicians. In this study, the authors were unable to
determine whether this was because of better management
per se or because neurologists were usually based in spe-
cialist centers and may have better intensive care support, or
both. Alternatively, there may be an element of selection
bias so that neurologists cared for less seriously ill patients.
In our study, the benefit appears to be due to better man-
agement because the rates of undertreatment, poor com-
pliance, infectious complications and drug-induced AEs
were different in the two treated groups. In an analogous
manner to the demonstration that NM subspecialty training
is useful in accurately predicting the likely cause of a
peripheral neuropathy [13], it appears that such specialist
training is also important in the management of MG.
Conclusion
Myasthenia gravis remains a challenging field, with a high
rate of UOs that are too often due to undertreatment, poor
compliance, infections and drug AEs. As about two-thirds
of the causes of UOs were due to potentially reversible
factors, our study supports the idea that there remains more
to be done in optimizing the management of MG, possibly
by organizing specialist treatment for all.
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